Cargando…
Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)
INTRODUCTION: Oncogenic alterations in RET occur in 1–2% of non-small-cell lung cancers (NSCLCs). The efficacy and safety of the first-in-class, highly selective, and potent RET inhibitor selpercatinib in Chinese patients with RET fusion-positive NSCLC remains unknown. METHODS: In this open-label, m...
Autores principales: | Lu, Shun, Cheng, Ying, Huang, Dingzhi, Sun, Yuping, Wu, Lin, Zhou, Chengzhi, Guo, Ye, Shao, Jingxin, Zhang, Wanli, Zhou, Jianying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340421/ https://www.ncbi.nlm.nih.gov/pubmed/35923928 http://dx.doi.org/10.1177/17588359221105020 |
Ejemplares similares
-
Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial
por: Cheng, Ying, et al.
Publicado: (2023) -
Selpercatinib monotherapy in a Chinese patient with RET fusion/EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report
por: Wu, Lin, et al.
Publicado: (2023) -
Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial
por: Lu, Shun, et al.
Publicado: (2023) -
Efficacy and safety of selpercatinib in Chinese patients with
advanced RET-altered thyroid cancers: results from the phase II
LIBRETTO-321 study
por: Zheng, Xiangqian, et al.
Publicado: (2022) -
Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
por: Subbiah, Vivek, et al.
Publicado: (2021)